- Home
- ACRS vs KFS Comparison
ACRS vs KFS Comparison
Compare ACRS & KFS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ACRS | KFS |
|---|---|---|
| Founded | 2012 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Property-Casualty Insurers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 311.0M | 353.7M |
| IPO Year | 2015 | 2013 |
Fundamental Metrics
Financial Performance| Metric | ACRS | KFS |
|---|---|---|
| Price | $3.50 | $10.18 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $9.75 | N/A |
| AVG Volume (30 Days) | ★ 2.5M | 79.7K |
| Earning Date | 05-07-2026 | 03-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 69.01 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $1,683,000.00 | ★ $134,996,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.24 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 23.42 |
| 52 Week Low | $1.05 | $7.28 |
| 52 Week High | $4.89 | $16.80 |
Technical Indicators
Market Signals| Indicator | ACRS | KFS |
|---|---|---|
| Relative Strength Index (RSI) | 50.91 | 36.00 |
| Support Level | $2.67 | N/A |
| Resistance Level | $3.86 | $14.83 |
| Average True Range (ATR) | 0.26 | 0.47 |
| MACD | -0.01 | -0.03 |
| Stochastic Oscillator | 46.32 | 21.59 |
Price Performance
Historical ComparisonAbout ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.
About KFS Kingsway Financial Services Inc. (DE)
Kingsway Financial Services Inc through subsidiaries operates in the extended warranty and business services industries in the United States. The company operates through segments namely, Extended Warranty and Kingsway Search Xcelerator. The Extended Warranty segment provides after-market vehicle protection services distributed by credit unions. The firm generates maximum revenue from the Extended Warranty segment in the form of Service fee and commission income.